Disc Medicine, Inc. (IRON) - Utang jangka dawa marang modal

Disc Medicine, Inc. is developing innovative hematological treatments through partnerships with scientific centers and patent exchanges. The creation of drugs for orphan blood pathologies ensures long-term financial stability. The quote characteristic (separate_debt_long_eq) stands at 0.09. The business is currently focusing on mutation therapy, where commercialization success and capital inflows depend entirely on safety approval from the FDA.

This indicator measures the proportion of liabilities with a maturity exceeding one year within the equity structure, determining the business's degree of financial resilience to long-term stress. For Disc Medicine, Inc. (IRON), which is depleting reserves on costly clinical trials, the long-term financial dependency ratio verifies the balance between borrowed funds and equity, signaling the company's level of reliance on external financing.